<DOC>
	<DOCNO>NCT00384020</DOCNO>
	<brief_summary>The purpose study understand genetic polymorphism influence efficacy side effect profile Paroxetine Escitalopram major depression treatment .</brief_summary>
	<brief_title>Clinical Pharmacogenomics Antidepressant Response</brief_title>
	<detailed_description>Despite remarkable progress recent decade modern psychopharmacotherapy , patient vary substantially response antidepressant , range total remission complete treatment failure . Adverse effect , often bothersome occasionally life-threatening , continue represent significant challenge patient clinician . Mechanisms responsible variability remain poorly understood . In addition , although less appreciated , substantial cross-ethnic variation psychotropic response often exist . Recent development field pharmacogenetics indicate genetic factor may account large part difference response . Specific genetic polymorphism affect function serotonin ( SERT ) system postulate predict effect antidepressant . Similarly , genetic mutation show exert predominant influence expression number drug-metabolizing enzyme , include cytochrome P-450 enzyme responsible biotransformation antidepressant . Polymorphisms gene control enzymes find strongly associate propensity various kind side effect . Capitalizing new development , propose study examine predictive value genetic polymorphism 400 patient DSM-IV major depression prospectively treat Escitalopram ( ECIT ) Paroxetine ( PAR ) . It postulate mutation affect function SERT predict response ECIT , polymorphism CYP2C19 associate side effect profile pharmacokinetics ECIT .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>selfidentified Taiwanese/Chinese ethnic background , report parent four three grandparent member ethnic group ; HAMD21 &gt; 17 plus MDE ( i.e. , current major depressive episode ) base SCID ; male female , , childbearing potential , agree use effective contraception include regular use contraceptive pill , intrauterine devise abstinence ; age &gt; = 18 ; capable give informed consent ; diagnosis schizophrenia , schizophreniform disorder , schizoaffective disorder , schizotypal disorder , psychotic depression , bipolar disorder ; current drug alcohol abuse dependence history drug alcohol abuse dependence within past 6 month ; unstable medical neurological condition likely interfere treatment depression ; history allergy antidepressant ; history seizure disorder ; pregnancy ; active suicidal ideation safety issue determine clinician suitable inclusion study ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Major Depression Disorder</keyword>
	<keyword>Antidepressant</keyword>
	<keyword>Pharmacogenomics</keyword>
	<keyword>Cytochrome P450</keyword>
	<keyword>Serotonin Transporter</keyword>
</DOC>